INVA · Innoviva, Inc.
$21.00
-0.48 (-2.23%)
At close · Aug 20
Market Cap
$1.55B
Shares
72.25M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.48
Open$21.45
Day$21.36–21.70
52W close$16.67–24.24
Avg vol 30d745K
Short int6.9M · 9.5% float · 11.5d
Short vol54%
Last earningsMay 8, 2024
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−2%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
64%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
−9%
trailing
YTD return
+7%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +47 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.54% of float · ▼ -1.8% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
306 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+63%
Y/Y
Gross margin
142%
contracting
EPS growth
+817%
Y/Y
Free cash flow
$195.8M
Valuation
P/E 4.9
below peers
Buyback
$68.6M
remaining
Balance sheet
$293.2M
net cash
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−2%
Neutral
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
64%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $22 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +47 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.54% of float · ▼ -1.8% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
306 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $21 · 64%
Range high $24
vs 200-day avg -1%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Armata Pharmaceuticals investments | $457.7M | as of June 30, 2026 | — |
| Investments held by ISP Fund | $34.5M | as of June 30, 2026 | — |
| IST U.S. net product sales | $36.6M | the second quarter | — |
| Net product sales | $51.77M | FY2026 Q2 | +45.9% |
|
|
|||
| Royalty revenue from Glaxo Group Limited | $59.8M | the second quarter of 2026 | — |
| Share repurchase amount during quarter | $31.4M | the second quarter of 2026 | — |
|
|
|||
| Shares repurchased during quarter | 1,403,247 | the second quarter of 2026 | — |
|
|
|||
| Shares repurchased since inception of share repurchase program | 2,602,168 | through the end of the second quarter of 2026 | — |
| Strategic healthcare investments | $669.5M | as of June 30, 2026 | — |
| IST net product sales growth | 37% | first quarter 2026 | — |
| Share repurchase program authorization | $125M | first quarter 2026 | — |
|
|
|||
| U.S. net product sales | $34.2M | first quarter 2026 | — |
|
|
|||
| U.S. net product sales growth | 29% | first quarter 2026 | — |
| Investment in Beacon Biosignals Series B Preferred Stock | $17.5M | October 2025 | — |
| Net product sales growth (year-over-year) | 77% | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INVA
this stock
Innoviva, Inc.
|
$1.55B | +7.5% | +62.6% | 4.9 | 9.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +24.0% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +8.9% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +491.3% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INVA | +3.2% | +0.2% | -8.8% | +2.4% | +7.5% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +3.7% | -2.7% | -20.3% | -0.5% | -5.3% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$125.00M
Spent (derived)
$56.40M
Remaining
$68.60M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1080014
CUSIP
45781M101
13F (30d)
279 filings
276 filers
Visit website
Investor relations